甲磺酸阿帕替尼治疗恶性肿瘤的相关研究进展

Research progress of apatinib mesylate in cancer treatment

近年来,抗血管生成的靶向治疗成为肿瘤治疗的热点并得到广泛应用。甲磺酸阿帕替尼是我国自主研制的小分子口服抗血管生成靶向药物,实际临床应用中对胃癌、肝癌、肺癌、乳腺癌、卵巢癌等恶性肿瘤具有良好的抗癌活性,但其针对不同恶性实体瘤的潜在作用机制尚未明确,且血药浓度监测及基因位点研究甚少。本文根据最新研究结果,从作用机制、临床应用、不良反应、血药浓度监测、基因多态性与疗效影响几个方面进行总结,为深入阿帕替尼相关研究及临床合理应用提供参考依据。

In recent years,targeted therapy of anti-angiogenesis has become a hot spot in clinical treatment and has been widely used.Apatinib mesylate is a small molecule oral anti-angiogenesis inhibitor independently developed in China.It has good anti-cancer activity against malignant tumors such as gastric cancer,liver cancer,lung cancer,breast cancer,and ovarian cancer in actual clinical applications,but its potential mechanism of action against different malignant solid tumors has not yet been clarified,and there are not a lot of researches on blood drug concentration monitoring or genetic loci about apatinib.Based on the latest basic and clinical research results,this article summarized the mechanism of action,clinical application,adverse reactions,blood concentration monitoring,gene polymorphism and efficacy in order to provide a reference basis for further research and clinical rational use of apatinib.